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Abstract 
Symptoms caused by bacterial, viral and malarial infections usually overlap and aetiologic diagnosis is difficult. Patient 
management in low-resource countries with limited laboratory services has been based predominantly on clinical 
evaluation and syndromic approaches. However, such clinical assessment has limited accuracy both for identifying 
the likely aetiological cause and for the early recognition of patients who will progress to serious or fatal disease. 
Plasma-detectable biomarkers that rapidly and accurately diagnose severe infectious diseases could reduce mor-
bidity and decrease the unnecessary use of usually scarce therapeutic drugs. The discovery of microRNAs (miRNAs) 
has opened exciting new avenues to identify blood biomarkers of organ-specific injury. This review assesses cur-
rent knowledge on the relationship between malaria disease and miRNAs, and evaluates how future research might 
lead to the use of these small molecules for identifying patients with severe malaria disease and facilitate treatment 
decisions.
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Background
The burden of infectious diseases disproportionately 
affects the African continent, where massive diagnostic 
needs have to be met with limited resources. Considera-
ble advances have been made in the management of Afri-
can patients with febrile illness and in ensuring that those 
who are severely ill can have access to hospital [1]. How-
ever, current evidence suggests that many of the existing 
guidelines are not followed [2], laboratory workload com-
promises quality, and prioritizing hospital admissions is 
rarely practised [3]. Moreover, access to the health sys-
tem remains severely compromised for African patients, 
particularly in the most rural areas. Efforts are needed to 
improve diagnostic capacity for the clinical management 
of patients in this challenging environment.
Pneumonia and malaria are two leading causes of 
morbidity and mortality in children aged under 5  years 
worldwide [4], especially in malaria-endemic countries, 
where diagnostic tools are scarce and access to adequate 
care is limited [5, 6]. More than 60  % of the estimated 
905,059 pneumonia deaths in 2013 among children 
<5  years occurred in 10 developing countries [7], and 
are mainly secondary to bacterial infections [8]. There 
were an estimated 214 million cases of malaria world-
wide (range 149–303 million) in 2015 and 438,000 deaths 
(range 236,000–635,000), with 91 % of all malaria deaths 
occurring in sub-Saharan Africa and children aged under 
5  years bearing the largest burden [9]. To reduce the 
number of deaths caused by pneumonia and malaria, 
early diagnosis is critical for a promptly administration of 
the adequate treatment.
An optimal management of malaria needs a correct 
diagnosis and a good assessment of severity. However, 
the distinction on clinical grounds between malaria and 
other infectious diseases, such as severe pneumonia, is 
not straightforward and has challenged clinicians for 
a long time [10–12]. Clinical signs of malaria in chil-
dren are highly unspecific and often overlap with those 
of other infections, such as pneumonia, bacteraemia or 
meningitis [13–16]. In such a context, severe malaria is 
difficult to differentiate from other infections, which 
often include the appearance of respiratory signs and 
fever. Even when a Plasmodium infection is confirmed, 
Open Access
Malaria Journal
*Correspondence:  alfredo.mayor@isglobal.org 
1 ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-
Universitat de Barcelona, Carrer Rosselló 153 (CEK building), 
08036 Barcelona, Spain
Full list of author information is available at the end of the article
Page 2 of 14Rubio et al. Malar J  (2016) 15:167 
causal attribution of symptomatology to malaria is not 
straightforward, as malaria-positive slides are a common 
incidental finding in areas where many people are semi-
immune to malaria and have high rates of asymptomatic 
parasite carriage [17]. Thus, the detection of parasites in 
the blood of sick patients is not a definitive proof of their 
association with the clinical symptoms.
The importance of this disease-overlap will depend 
upon the epidemiology of pathogens in each particular 
setting, but also on the severity of the presentation and 
the age of the patient. One consequence of falling malaria 
transmission rates [18, 19] is that presumptive treatment 
is not as safe as it was a decade ago. This is because the 
malaria-attributable fraction of fevers is now substan-
tially lower and therefore the relative likelihood of failing 
to treat alternative causes of severe infection has become 
higher [20], potentially leading to avoidable morbid-
ity and mortality. Moreover, overdiagnosis of malaria in 
endemic regions increases the use of anti-malarial drugs 
which contributes to the development of anti-malarial 
drug resistance [21], and also burdens health services 
with unaffordable costs [22]. Additionally, diagnosis is 
hindered by the broad diversity of pathophysiological 
pathways, leading to the different syndromic presenta-
tions associated with severe malaria [23]. Current World 
Health Organization recommendations state that it is 
essential to give promptly full doses of effective paren-
teral (or rectal) antimalarial treatment in the initial treat-
ment of severe malaria, followed by a full dose of effective 
artemisinin-based combination therapy orally [24]. The 
identification at early infection stages of those individu-
als at risk of severity and death can help to save lives by 
providing a prompt aggressive treatment. Biomarkers 
capable to predict the likelihood of complications both at 
initial presentation and during antimalarial and support-
ive treatment could be used to guide the management of 
patients most at risk of severe pathologies. Finally, the 
diagnostic revolution that the introduction of rapid diag-
nostic tests (RDTs) has meant to the diagnosis of malaria 
has also had the counter-effect of leaving clinicians with 
a significant amount of non-malarial fevers with no diag-
nostic filiation.
The diversity of the causes of fever, most of which can-
not be diagnosed on clinical grounds alone, calls for the 
development of point-of-care tests to make rapid clini-
cal decisions in developing countries. Any improvement 
on clinical endpoints to differentiate malaria from other 
infectious diseases with no requirement of laboratory 
facilities might help management of treatment. Further 
improvement could be brought by integrating host bio-
markers able to predict children at risk of dying. Sev-
eral efforts have been made in recent years to evaluate 
multiple host biomarkers in the differential diagnosis of 
malaria, bacterial or viral infections, but to date no single 
satisfying biomarker has shown a clinical utility to reli-
ably distinguish these three microbial aetiologies [6, 25, 
26]. A new area of research that holds great potential for 
individualized medicine is the study of small non-coding 
RNAs. Since the discovery of microRNAs (miRNAs) in 
2001 [27], numerous studies have attempted to evaluate 
them as promising biomarkers for several human disor-
ders such as cancer, cardiovascular diseases, diabetes, 
exposure to toxic compounds, and infectious diseases [28, 
29]. This is so because dysregulation of the expression 
of these tiny molecules, which control in an extremely 
accurate way metabolic processes such as apoptosis, cell 
proliferation and differentiation [30], is usually indica-
tive of pathological disorders or physiological changes 
in the individual. For that reason many studies in the last 
few years have tried to correlate aberrant miRNA levels 
with specific disease in order to find new biomarkers and 
diagnosis tools. This review aims to describe the current 
knowledge about miRNAs in malaria and discuss their 
potential as biomarkers of pathologies associated with 
this infectious disease.
Malaria disease
In 2015 malaria was endemic in 97 countries, with 3.2 
billion people, almost half of global population, living 
at risk of infection. This scourge is responsible for over 
200 million annual cases, and nearly half a million annual 
deaths every year [31]. Malaria can be caused by five spe-
cies of Plasmodium: Plasmodium falciparum, P. vivax, 
P. malariae, P. ovale, and P. knowlesi. Plasmodium is an 
apicomplexan parasite with a complex life cycle involv-
ing two different hosts: mosquitoes as vectors and ver-
tebrates as the final host. Anopheline mosquitoes inject 
malaria parasites (sporozoites) into the subcutaneous tis-
sue of the vertebrate host. Sporozoites travel to the liver 
and infect the hepatocytes, where each one develops into 
thousands of merozoites. In the blood, merozoites grow 
inside red cells through successive cycles of invasion, 
asexual replication and release of newly formed merozo-
ites. Some of these merozoites will be developed into sex-
ual forms (gametocytes) which will be taken up by other 
mosquitoes when they feed from infected blood [32]. In 
the case of P. vivax and P. ovale, parasites may persist in 
the liver as dormant stages called hypnozoites, eventually 
leading to relapses weeks, months and years after a pri-
mary infection [33].
All the clinical symptoms associated with malaria are 
caused by the asexual erythrocytic or blood-stage para-
sites. The rupture of Plasmodium schizont stage-infected 
erythrocytes releases merozoites into the bloodstream 
[34], as well as parasite-derived toxins such as haemo-
zoin pigment, glycosyl-phosphatidyl-inositol molecules 
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that anchor a diverse range of proteins to the surface of 
malaria parasites, and other by-products of the parasite. 
These toxins stimulate macrophages and other innate 
immune cells to produce pyrogenic-inflammatory medi-
ators and cytokines that stimulate thermoregulatory 
regions of the brain to increase body temperature, lead-
ing to the acute periodic febrile episodes [35]. Although 
most of the malaria infections are associated with 
uncomplicated malaria, a percentage of them evolve into 
severe disease, especially those infections caused by P. 
falciparum. Severe malaria in African children encom-
passes at least three main clinical syndromes that can 
occur alone or in combination: severe malarial anaemia, 
cerebral malaria and respiratory distress (often secondary 
to metabolic acidosis [36]). Symptoms of severe malaria 
are similar to those of many other diseases that are com-
mon in malaria-endemic countries, such as septicaemia, 
severe pneumonia and typhoid fever [37].
In terms of the underlying pathophysiology, these 
severe forms of malaria infection, mainly characteristic 
of P. falciparum, have been attributed to the ability of 
erythrocytes infected by this species to sequester in vital 
organs of the human host such as brain [38], placenta [39] 
and bone marrow [40] (Fig. 1). Erythrocytes infected by 
mature stages of the parasite adhere to cellular endothe-
lium through interactions with human receptors such 
ICAM-1, CD36, gC1qR endothelial protein C receptor 
(EPCR), to non-infected erythrocytes forming ‘rosettes’ 
or to platelets to form agglutinates [41, 42]. Although 
there is still some debate, severe malaria has been asso-
ciated with some of these cyto-adhesive phenotypes [42, 
43] and the subsequent microvascular obstruction result-
ing from the accumulation of infected erythrocytes in 
vital organs [44]. The parasite protein expressed on the 
surface of infected erythrocytes that mediates this cyto-
adhesion has been identified as a very large protein called 
P. falciparum erythrocyte membrane protein 1 (PfEMP1), 
encoded by approximately 60 var genes per genome [45]. 
Sequestration of P. falciparum in the microvasculature is 
thought to avoid clearance of the parasite in the spleen. 
However, such accumulation of parasites provokes 
increasing vascular resistance, inflammatory reactions 
and tissue damage [46]. The ensuing distal tissue hypoxia 
can increase host anaerobic glycolysis due to a mismatch 
between tissue oxygen supply and requirement [47, 48], 
contributing to malarial acidosis [48]. Moreover, bind-
ing of PfEMP1 to host receptors such as a EPCR can also 
contribute to intensive inflammation through the block-
ing of cytoprotective functions mediated by the activated 
protein C (APC) cellular pathway [43]. However, not all 
the sequestration events may be exclusively mediated by 
cyto-adhesion of the parasite. Decreased deformability 
of erythrocytes infected by immature gametocyte stages 
[49] may play a role in their enrichment in the bone mar-
row [40, 50], potentially disturbing haematopoietic func-
tions of this organ. Moreover, severe malaria can also 
Fig. 1 Sequestration of Plasmodium falciparum-infected erythrocytes in the capillaries of different human tissues. Tissue specimens for histological 
analysis were fixed in 10 % neutral buffered formalin-paraffin embedded and stained with haematoxylin and eosin (H and E). a Bone marrow (H 
and E, 400x), b Central nervous system (H and E, 400x), c Heart (H and E, 400x), d Kidney (H and E, 400x), e Lung (H and E, 400x), f Placenta (H and E, 
400x). Arrows indicate infected erythrocytes (blue). Photographs by Paola Castillo and Jaume Ordi
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result also from an excessive host inflammatory response 
following exposure to malaria ‘toxins’ [51] or metabolic 
damage of critical organs [23]. These mechanisms may 
explain severe malaria syndromes such as lactic acidosis 
that result from a combination of anaerobic glycolysis in 
tissues where sequestered parasites interfere with micro-
circulatory flow, lactate production by the malaria para-
sites, and a failure of hepatic and renal lactate clearance 
[23].
Malaria diagnostics
Malaria case management, which consists of prompt 
diagnosis and effective treatment, remains a vital com-
ponent of malaria control and elimination strategies [24]. 
High-quality malaria diagnosis is important in all settings 
as misdiagnosis can result in significant morbidity and 
mortality [14]. Recent experience in malaria case man-
agement has shown that using appropriate diagnostic 
tools such as malaria RDTs has the potential to improve 
rational use of anti-malarial drugs [52]. However, it has 
often been accompanied with an increased antibiotic 
prescription that is unlikely to provide clinical benefit in 
most cases [53], but rather exposes the patient to unnec-
essary adverse events and increases the development of 
antimicrobial resistance.
Malaria is classically identified by optical microscopic 
examination of Giemsa-stained peripheral blood smears. 
Although microscopy is easy to perform and cost effec-
tive, the technique is time consuming and requires 
maintaining the proficiency of microscopists through 
extensive training and quality-control procedures. Theo-
retically, thick film microscopy by highly skilled techni-
cians can detect approximately 20–50 parasites/µL, with 
detection limit of 100–500  parasites/µL in most field 
settings [54]. However, the fact that P. falciparum can 
sequester in vital organs by cyto-adhesion to certain host 
receptors, complicates the diagnosis as parasites might 
be present in tissues, such as the placenta in pregnant 
women or the brain, but absent in peripheral blood [55].
RDTs employ immunochromatographic methods to 
detect parasite proteins [P. falciparum histidine-rich pro-
tein 2 (HRP2)] or glycolytic enzymes (Plasmodium lactate 
dehydrogenase and aldolase) with a working threshold of 
approximately 100 parasites/µL [56], although more sen-
sitive RDTs are currently under development. RDTs do 
not require electricity or a water source, are simple to use, 
easy-to-interpret and relatively cost effective. The quanti-
fication in plasma of HRP2 has been shown to allow the 
estimation of total body parasite biomass with acute P. fal-
ciparum malaria [57], suggesting that detection of HRP2 
may identify parasites sequestered away from peripheral 
blood [58]. However, HRP2-based RDTs can remain posi-
tive even after an infection has been successfully treated, 
as the antigen remains in circulation for days to even sev-
eral weeks after parasitaemia has cleared, something that 
hampers their utilization for fevers occurring short-term 
after a malaria episode [59]. Moreover, parasites lacking 
the hrp2 gene are beginning to emerge, possibly because 
they avoid detection by HRP2-based tests [60].
Polymerase chain reaction (PCR) is now well recog-
nized as the most sensitive method to detect malaria par-
asites. Primers targeting the 18S ribosomal gene specific 
for any Plasmodium species are most commonly used. 
Nested PCR [61] was the standard method until recently, 
when real-time PCR methods have become increasingly 
more common [62, 63]. Different PCR methods have 
limits of detection ranging from 2 to 2000  parasites/µL 
[64, 65]. Being the most sensitive and accurate diagnostic 
tool, its wider implementation in malaria-endemic coun-
tries appears challenging, because it needs qualified per-
sonnel, expensive infrastructure and reagents, as well as 
certain storage conditions of reagents. Other techniques 
that are being developed for the diagnostic of malaria 
parasites include loop-mediated isothermal amplification 
(LAMP), a DNA amplification method in which specific 
genes are made into loops so that DNA amplification 
can occur continuously [66], RNA hybridization assays 
[67], laser desorption mass spectrometry (LDMS) which 
detects haem from haemozoin as a marker of malaria 
infection [68], and flow cytometry and automated blood 
counters which detect haemozoin-containing leukocytes 
[69].
These diagnostic techniques still have limitations to 
detect some parasite stages and discriminate between 
disease states. Hypnozoites from P. vivax and P. ovale 
cannot be detected with currently available diagnostic 
tools and are not cleared upon treatment with routinely 
administered anti-malarial drugs, unless primaquine (a 
drug that requires at least seven to 14  days of adminis-
tration and can cause severe haemolysis in people with 
glucose-6-phosphate dehydrogenase deficiency) is added 
to the treatment [70]. A tool to detect such dormant 
forms would be extremely useful for current elimina-
tion efforts, as hypnozoites constitute a parasite reservoir 
that can cause blood-stage infections at a later point in 
time [71]. Also, most common diagnostic tools cannot 
discriminate between severe or uncomplicated malaria. 
Current diagnosis tools for the detection of malaria, ben-
efits and challenges are summarized in Table 1. However, 
other approaches have been assessed for the diagnosis of 
life-threatening malaria. Ophthalmoscopy has helped to 
increase accuracy of severe malaria diagnosis by allowing 
the visualization in real time of certain signs believed to 
be pathognomonic for the diagnosis of cerebral malaria, 
such as retinal whitening, papilloedema, vessel colour 
changes, and white-centred haemorrhages [72]. Any 
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parameter associated with malaria-attributable severe 
disease could help to improve severe malaria diagnosis.
New biomarkers in malaria disease
Several molecules have been proposed to discriminate 
the aetiology of severe infections. Biomarkers to differ-
entiate viral from bacterial infections have been evalu-
ated mostly in the developed world to support clinical 
diagnosis and to be applied as RDTs. Despite disparity in 
results [73, 74], procalcitonin (PCT) and C-reactive pro-
tein (CRP) are routinely used in many emergency depart-
ments and intensive care units of developed countries as 
a rapid screening method to guide the aetiological diag-
nosis in children with pneumonia, assuming higher levels 
of both markers in bacterial infections when compared 
to viral ones. However, distribution between clinical 
groups has been shown to overlap in presence of malaria 
parasites [75], suggesting that malaria infection should 
be taken into consideration if using PCT or CRP to dif-
ferentiate viral from invasive bacterial pneumonia in 
malaria-endemic areas. Haptoglobin in combination with 
lipocalin 2 has also been shown to allow discrimination 
between pneumonia and malaria in children with res-
piratory distress [26], and alone or in combination with 
tumour necrosis factor receptor 2 (TNFR2) or interleu-
kin-10 (IL10), and tissue inhibitor of metalloproteinases 
1 (TIMP1) has recently been suggested to allow accurate 
classification of patients into bacterial, malarial and viral 
aetiologies [25]. Erythropoietin (EPO), a glycoprotein 
hormone principally produced by the kidney’s peritu-
bular capillary endothelial cells in response to hypoxia, 
has been shown to be increased in African children with 
malaria [76–80], suggesting that EPO might be a good 
indicator of malaria-attributable disease. However, the 
utility of EPO to distinguish malaria-attributable severe 
disease has been questioned due to the overlap of EPO 
values between children with severe malaria and inva-
sive bacterial infection [81]. Similar limitations have been 
described for serum lactate/pyruvate [47, 48], with no 
differences found when comparing children with severe 
malaria and invasive bacterial infection [81].
Potential serological markers for cerebral malaria have 
been also suggested. Angiopoietin factors, which regu-
late the maintenance of vascular integrity, have been 
shown to be differentially regulated in patients with 
cerebral malaria. Compared to healthy controls, cer-
ebral malaria patients have been shown to have reduced 
levels of angiopoietin 1 (ANG1), elevated levels of angi-
opoietin 2 (ANG2) and higher ANG2/1 ratios [82]; 
moreover, low ANG1 levels at presentation predicted 
subsequent mortality in children with cerebral malaria. 
Also, increases of a combination of multiple host mark-
ers of inflammation and endothelial activation, such as 
ICAM-1, sTie-2 and sFlt-1, have been observed in cer-
ebral and severe malaria compared to uncomplicated 
malaria as being able to predict mortality [83]. Finally, 
levels of circulating HRP2 have been shown to predict 
parasite sequestration in tissues [57]. Moreover, several 
Table 1 Current diagnosis tools for the detection of malaria, benefits and challenges
Method Detection Benefits Limitations
Clinical diagnosis Observation of symptoms Fast and inexpensive Cannot detect asymptomatic malaria
Some symptoms overlap with other 
diseases
Giemsa microscopy Detection of parasites in blood smears Fast and inexpensive Requires trained personnel
Able to differentiate malaria  
species
Requires maintenance of infrastruc-
tures
Able to quantify parasites Need to establish good quality controls 
and quality assurances
Cannot detect sub-microscopic infec-
tions
Rapid diagnosis test (RDT) Detection of malaria antigens and 
enzymes in blood
Fast (5–20 min) Variable sensitivity
Simple and easy to interpret Cross-reactivity with other blood 
factors
No electricity needed Affected by environmental conditions
Cost effectiveness vary with malaria 
prevalence
Cannot detect sub-RDT infections
Polymerase chain reaction (PCR) Detection of parasite DNA by PCR High sensitivity and specificity Cost and technical limitations makes it 
not applicable in daily clinical workDetermination of mixed infections
Able to quantify parasites
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studies have explored the utility of HRP2 concentrations 
as a risk factor for mortality in severe malaria [57, 84–
86]. Although concentrations were found to be higher in 
patients dying with severe malaria, the U-shaped curve 
describing the relationship between HRP2 and mortality 
risk [84] suggested a limited applicability of quantitative 
HRP2 as a prognosis marker. From the side of the host, 
several biomarkers [PCT, CRP, ICAM, ANG2, tumour 
necrosis factor-α (TNF-α), IFN-gamma-inducible pro-
tein 10 (IP-10)] have demonstrated a consistent statis-
tical association with mortality in patients with severe 
or cerebral malaria in two or more studies [83, 85, 87]. 
All these molecules have been suggested as promising 
clinically informative biomarkers for severe malaria, 
although additional studies are still needed to address 
their utility as prognostic biomarkers and potential 
therapeutic targets in severe malaria. Other molecules 
such as miRNAs are currently being evaluated as indi-
cators of malaria disease stages and progression, as well 
as the risk of death.
miRNA structure and function
miRNAs are small, endogenous, non-coding RNAs of 
about 21–23 nucleotides that regulate gene expression 
at a post-transcriptional level. Together with the small 
interfering RNAs (siRNA), miRNAs are one of the two 
types of small RNA molecules central to the gene silenc-
ing pathway called RNA interference (RNAi). They incor-
porate into the RNA-induced silencing complex (RISC), 
and bind to 3′ untranslated regions (UTR) or 5′UTR of 
the messenger RNAs (mRNAs) with imperfect com-
plementarity blocking translation of the target mRNA. 
Since the discovery in 2001 of the first miRNAs lin-4 and 
let-7 in Caenorabditis elegans [27], 35,828 mature miR-
NAs have been found in 223 species of animals, plants, 
fungi, protozoa, and viruses (miRbase, version 21 [88]). 
MiRNAs regulate different processes in animals, such 
as developmental timing, patterning and embryogen-
esis, differentiation and organogenesis, growth control, 
and programmed cell death or differentiation of stem 
cell lineages [89]. miRNAs also have an important role in 
modulating innate immune responses, such as differen-
tiation, survival and function of immune cells, cytokine 
responses and intracellular signalling pathways [90].
miRNAs undergo molecular processing before becom-
ing mature. Most of them are transcribed in the nucleus 
as long primary transcripts by RNA polymerase II. These 
primary transcripts can have more than one miRNA 
folded in hairpin structures called precursor miRNAs 
(pre-miRNAs) that are released from the primary tran-
script when they are cut by the ribonuclease Drosha (a 
RNase III). These pre-miRNAs are transported to the 
cytoplasm by the enzyme exportin 5 and recognized by 
another RNase III (Dicer) that cleaves the hairpin to pro-
duce a miRNA duplex. One of the strands of the duplex 
is incorporated into the RISC combined with the pro-
tein argonaute, which has endonuclease activity directed 
against mRNA strands that display extensive comple-
mentarity to their bound miRNA. The miRNA then 
guides the argonaute-RISC to the target mRNA, binds 
to the imperfectly paired miRNA sites located within it, 
and blocks transcript translation, eventually leading to 
mRNA degradation [30].
miRNAs can easily get into the circulation from spe-
cific cells and tissues through transportation in exosomes 
and microvesicles or associated to lipoproteins [high-
density lipoproteins (HDL) and low-density proteins 
(LDL)] or protein complexes, including argonaute 2 [91]. 
The mechanisms by which miRNAs are actively exported 
from cells and packaged into appropriate carriers are cur-
rently poorly understood, but the evidence shows that 
some miRNAs are selectively exported from certain type 
of cells [92]. There are specific signalling pathways that 
regulate miRNA release [93] and each biological fluid 
has a distinct miRNA signature that is consistent among 
different individuals [94]. Despite the high amount of 
RNases in the body fluids, circulating miRNA are stable 
due to the protection they get through the vesicles or 
binding proteins, and are internalized into recipient cells, 
retaining their ability to recognize and repress mRNA 
targets [95].
Circulating miRNAs as biomarkers of disease
A good biomarker has to be specific, with high sensitiv-
ity and able to make accurate, reliable and reproducible 
diagnostic predictions. Also, they have to be robust and 
as little invasive as possible. miRNAs have been shown to 
be rapidly released from tissues into the circulation with 
the development of pathology, and to reflect disease sta-
tus as well as organ damage and injury [96]. As secreted 
miRNAs can be detected in biological fluids such as 
plasma [97] and are stable even after long and severe 
storage conditions, they are currently being explored as 
promising non-invasive biomarkers to assess and moni-
tor the body’s pathophysiological status [98]. For this rea-
son, there have been huge efforts during the last years to 
profile miRNAs in serum, plasma, urine, and other bio-
fluids, and relate them to different diseases.
There are more than 1000 studies about miRNAs as 
biomarkers in human diseases, most of them in different 
types of cancer. Carcinogen cells actively secrete specific 
miRNAs into the circulation, sometimes supporting the 
growth and progression of the tumour [99]. Given that 
the secretion of these tumour-specific miRNAs can be 
found in different stages of the disease, their detection 
may be useful for early diagnosis and prognosis. However, 
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circulating miRNAs can also be biomarkers of other dis-
eases, such as inflammatory and neuropathic pain con-
ditions [100], neurologic pathologies [101], endocrine 
[102], and cardiovascular disorders [103]. Although the 
information about circulating miRNAs as biomarkers in 
different diseases is abundant and increases on a daily 
basis, partly thanks to new advances in next-generation 
sequencing and the development of new arrays and 
miRNA profiling methods, commonly reported miRNA 
biomarkers have been found associated with a wide range 
of conditions and outcomes. Moreover, findings have not 
been reproduced in all the studies, pointing to the need 
for standardized sampling and processing protocols in 
order to identify reliable biomarkers [104].
The existence of tissue-specific miRNA signatures has 
been suggested in several studies [105–108], reinforcing 
the concept that circulating miRNAs can be informative 
of the tissue where pathology is occurring. Tissue-spe-
cific miRNA signatures have been described in different 
cell types [105, 106]. Specificity of circulating miRNAs 
from different injured organs has also been show in 
rats [107], with increases of miRNA concentrations in 
plasma associated with injuries in liver, muscle or brain. 
Human miRNA profiles have been shown to reflect the 
developmental lineage and differentiation state of the 
tumours, allowing the classification of different types 
of cancer [108]. Finally, a database (http://bioeng.swjtu.
edu.cn/TSmiR) has been developed to provide informa-
tion on interaction maps of transcription factors and 
tissue specific miRNAs from experimentally validated 
and predicted data [109]. miRNAs also have the poten-
tial of being informative of pathological processes asso-
ciated with infections. When bacteria, viruses or other 
pathogens enter in the organism, several hundred host 
genes are altered and miRNAs act to clear the patho-
gen and at the same time to avoid consequences of dys-
regulated gene expression [90]. There are some studies 
about aberrant miRNA expressions during viral infec-
tions, including hepatitis B virus [110], hepatitis C virus 
[111], human immunodeficiency virus [112], Epstein Barr 
virus [113], bacterial pneumonia, and tuberculosis [114, 
115] as well as some parasitic infections [116]. In filarial 
infections, parasite-derived miRNAs has been detected 
in the circulation of the host [117] and some nematode 
parasites can release exosomes with small RNAs to reg-
ulate innate immunity [118]. Few miRNAs have been 
found to be prominently expressed in mice infected by 
the apicomplexa Toxoplasma gondii [119]. Specificity of 
miRNAs has been show in Toxoplasmosis experimental 
infections compared to mice infected with P. berghei, P. 
yoelii, P. chabaudi, Cryptosporidium parvum, Mouse 
hepatitis virus, and Staphylococcus aureus [119], or in 
different types of lung affections, lung cancer, pulmonary 
tuberculosis, and pneumonia [115], but very little data is 
available on the differential host miRNA expression asso-
ciated with different types of infections, as most stud-
ies identify dysregulated miRNAs compared to healthy 
controls.
miRNAs and malaria infection
Although it is known that miRNAs regulate the immune 
system [120] and may play a major role in the regulation 
of host responses to Plasmodium infection, the current 
knowledge about the role of miRNAs in malaria disease 
is limited.
Small RNAs in Plasmodium, anopheline vectors and host 
erythrocytes
Plasmodium species lack the canonical RNAi machin-
ery of other eukaryotes. No dicer or argonaute proteins 
have been found in any of the ten species of Plasmodium 
with sequenced genome available, and exhaustive analy-
ses using RNA-based gene silencing approaches have 
revealed that Plasmodium lacks the enzymology required 
for RNAi-based ablation of gene expression [121]. The 
absence of RNAi machinery in Plasmodium is not sur-
prising assuming that RNAi could initially have evolved 
as a host defence mechanism against viruses and trans-
posons. Plasmodium is not affected by viruses, and some 
authors consider that the loss of RNAi machinery in 
some parasites may provide them with an advantage to 
develop new strategies to escape host defences [122, 123]. 
Although there is no canonical mechanism for RNAi 
in Plasmodium, several studies have shown successful 
down-regulation of gene expression using dsRNA, sug-
gesting the existence of non-canonical RNAi pathway, 
albeit not found until now [124–126].
To complete the complex life cycle of Plasmodium, 
gametocytes of the parasite have to be taken from the 
blood of infected vertebrate hosts by female Anoph-
eles mosquitoes. Plasmodium parasites then invade the 
midgut of the mosquito, a critical step for the parasite 
because the host tries to eliminate the infection. The 
knockdown of mosquito dicer and argonaute 1 has been 
shown to lead to increased sensitivity to Plasmodium 
infection [127], suggesting that impairment of miRNA 
maturation in the mosquito may alter translational regu-
lation of a variety of target genes that affect the parasite 
development in the invertebrate host. However, some 
studies have shown that the dysregulation of miRNA 
expression during Plasmodium infection in the mosquito 
is dependent on the stages along parasite progression 
[128, 129].
All miRNAs isolated from malaria-infected erythro-
cytes have been confirmed to be of human origin, sug-
gesting there are no miRNAs of Plasmodium [130, 131]. 
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This is in contrast to the large number of miRNAs that are 
expressed by the closely related protozoan Toxoplasma to 
regulate host gene expression [132]. However, it has been 
suggested that host miRNAs present in human eryth-
rocytes may translocate into the parasite, some of them 
forming a chimera with Plasmodium mRNAs to block 
their translation [133]. In particular, the translocation of 
miR-451, a very abundant miRNA in sickle erythrocytes 
[134] and its integration into essential parasite messenger 
RNAs, has been shown to result in translational inhibi-
tion via impaired ribosomal loading. Such a mechanism 
was suggested to represent a unique host defence strat-
egy against complex eukaryotic pathogens and may 
contribute to the cell-intrinsic resistance to malaria char-
acteristic of sickle cell anaemia. To our knowledge, this 
process was only observed in in  vitro analyses, with no 
further replication of this observation in biological sam-
ples collected from naturally exposed human popula-
tions, leaving many questions unresolved, such as the 
mechanism by which the miRNAs enter in Plasmodium 
and recognize target mRNAs, if it only happens in sickle 
cells or in all erythrocytes, and whether these miRNAs 
from the erythrocyte can get into the circulation and 
attack surrounding infected cells. Other small regulatory 
RNAs recently found in malaria parasites, such as circu-
lar RNAs (circRNAs) [135], which have been suggested to 
act as miRNA sponges [136], may also be involved in the 
regulation against the defences of the host.
miRNA defence against Plasmodium in vertebrate hosts
Only four studies have looked for abnormal regulation 
of host miRNAs after a Plasmodium infection in rodent 
models. Reprogramming of host miRNA expression 
was observed in the female mouse liver after a primary 
infection with P. chabaudi. These changes persisted 
during re-infection in mice that have acquired some 
level of anti-malarial immunity, suggesting that some 
miRNAs may regulate the development of protective 
immunity against malarial blood stages of P. chabaudi 
[137]. Nevertheless, it was not possible to correlate the 
changes in expression of these miRNAs with specific 
immune responses. A second study showed miRNA 
differences between P. berghei infected mice with cer-
ebral and non-cerebral malaria. Alterations of certain 
miRNAs coincided with increased levels of circulating 
inflammatory cytokines and apoptosis within the brain 
[138]. A third study found that most miRNAs species 
were downregulated in blood and liver after P. chabaudi 
infection. Although authors suggested that alterations 
of miRNAs allowed the upregulation of numerous tar-
get genes in response to infection, causal relationship 
between altered miRNA levels and pathology cannot be 
established [139]. Finally, mice injected with genetically 
attenuated parasites (GAP), which arrest in the liver and 
induce sterile immunity, were observed to have a sig-
nificant increase of miR-155 in their livers, especially 
pronounced in non-parenchymal cells, including liver-
resident macrophages (Kupffer cells) [140]. More impor-
tantly, the GAP’s protective capacity was improved with 
the administration of miR-155 using adeno-associated 
virus8 (AAV8), opening the path to the future use of 
miRNAs as malaria treatment.
Very little is known about the potential of plasma 
miRNAs as markers of Plasmodium infections. A study 
compared the level of few miRNAs detected by quanti-
tative PCR in the plasma of 19 individuals infected with 
malaria (three P. falciparum infections and 16 P. vivax 
infections) with levels of 19 non-infected controls. The 
decrease of two miRNAs, miR-451 and miR-16, was cor-
related not only with the infection of Plasmodium but 
also with its severity, defined on the basis of parasite 
densities [141]. However, the study was limited by the 
reduced number of patients and by the lack of a group 
of individuals infected with other pathogens to support 
that the differences observed in miRNAs were specific to 
the Plasmodium infection. Moreover, the down-regula-
tion of miR-451, the most abundant miRNA in human 
erythrocytes, is surprising given that malaria infections 
usually generate high haemolysis and therefore release 
miRNAs from erythrocytes. Further studies are needed 
to explore the value of miRNAs as biomarkers of malaria 
infection.
miRNAs as biomarkers in malaria disease
The discovery of miRNAs has opened exciting possibili-
ties to identify blood biomarkers of organ-specific injury. 
The content of miRNAs in the host is influenced by 
host-pathogen interactions, as has been shown for bac-
teria, viruses and apicomplexan parasites [137, 138, 142], 
including malaria parasites. Importantly, cyto-adhesion 
of P. falciparum to host receptors can trigger intracel-
lular signals in target cells [143] and potentially affect a 
wide range of cellular responses regulated by miRNAs, 
such as the expression adhesion molecules [144], vascu-
lar inflammation and parenchymal damage of bone mar-
row cells [145]. These previous evidences suggest that 
P. falciparum, although not able to produce miRNAs, 
may manipulate host miRNAs, pointing to the potential 
of these small molecules to not only shed light on the 
molecular mechanisms involved in severe malaria and 
sickle cell resistance [133], but also to assess the degree of 
vital organ dysfunction associated with parasite seques-
tration, which is believed to constitute a key pathogenic 
event in P. falciparum [146]. Thus, miRNAs secreted by 
host tissues damaged by P. falciparum sequestration, for 
instance at the brain, lung, spleen or liver, might have the 
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potential to be developed into a biomarker of malaria-
specific severe disease (Fig. 2). If differentially expressed 
in severe malaria patients compared to uncomplicated 
malaria or to other severe pathologies, detection of sub-
picomolar levels of miRNAs in blood [33] associated with 
P. falciparum sequestration may allow discriminating 
infected individuals with significant parasite sequestra-
tion from those in whom the parasitaemia is unrelated 
to the cause of severity [147]. Such an approach might 
allow the differentiation between true severe malaria 
from cases of incidental parasitaemia among individuals 
presenting at health centres with a severe infection. How-
ever, the fact that severe malaria can also result from an 
excessive host inflammatory response following exposure 
to malaria toxins imposes potential limitations to the link 
between all severe pathologies, parasite sequestration 
and production of tissue-specific miRNAs. Further stud-
ies are needed to understand if exposure to these malaria 
toxins can affect miRNA production by immune cell 
populations and be used to distinguish underlying mech-
anisms of severe malaria.
Composite diagnostics, including nucleic acid ampli-
fication of the pathogen and miRNA detection, to ascer-
tain the pathological cause of the severe disease could 
thus guide effective therapy, ensuring that children receive 
prompt and correct treatment, and reducing the develop-
ment of resistance. Such miRNAs can be also the basis 
for new diagnostic tools to predict malaria infections at 
risk of progression to severe disease that may require a 
more aggressive treatment. Moreover, miRNAs associ-
ated with malaria-related pathologies may also be applied 
to track the success of treatments against severe malaria 
cases, to generate estimates of malaria mortality rates, to 
evaluate outcomes in severe malaria clinical trials, and 
to improve measurements of the impact of future inter-
ventions against severe malaria. Finally, miRNAs could 
be also informative of the initial stages of liver infection, 
including hypnozoites in the case of P. vivax or P. ovale 
Fig. 2 Potential links between human severe malaria physiopathology and miRNAs: a proposed model. Upon infection with P. falciparum, infected 
liver cells or tissues affected by parasite sequestration, such as the placenta, bone marrow or the brain, may produce tissue-specific miRNAs that are 
released to blood circulation. Detection of such miRNAs may allow discriminating between infected individuals with significant parasite sequestra-
tion and those in whom parasitaemia is unrelated to the cause of severity, and guide effective therapy. miRNAs might also be the basis for new 
diagnostic tools to predict malaria infections at risk of progression to severe disease, or of those asymptomatic infections that may progress to 
symptomatic malaria. Finally, miRNAs could be informative of the presence of parasites hidden in the liver (P. vivax or P. ovale hypnozoites)
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[71], hidden parasites in the bone marrow and its associ-
ated pathology eventually leading to severe anaemia [40], 
and of those asymptomatic infections that may progress 
to symptomatic malaria [17]. Finally, longitudinal assess-
ment of miRNAs during the course of infections, includ-
ing comparisons between asymptomatic and symptomatic 
individuals as well as severe malaria cases during treat-
ment and after resolution, could allow the identification of 
miRNA signatures with value as a prognosis marker.
Robust and affordable point-of-care tests based on 
miRNA detection with laminar flow-assisted dendritic 
amplification on power-free microfluidic chip [148], 
or future field-deployable nucleic-acid based methods, 
would be useful for clinicians working in remote set-
tings to improve their management of patients, as well 
as a more targeted allocation of resources at the health 
policy level. Current technologies do not allow the use 
of these devices in daily routine, especially in malaria-
endemic countries. However, many efforts are being done 
to develop more affordable tools to detect miRNAs of 
diagnostic or prognostic value, as they can be potentially 
applied to different types of disease. New approaches 
are under development, such as detection methods 
based in fluorescence [149] that do not required previ-
ous amplification, or biosensors which can be used in 
portable devices [150]. Moreover, miRNA-based thera-
peutics based on anti-miR inhibitors or miRNA delivery 
are rapidly evolving, with some miRNAs currently start-
ing their clinical development phase, such as MRX34, a 
liposome-encapsulated miR-34 mimic which inhibits 
multiple oncogenic pathways as well as stimulates anti-
tumour immune response to induce cancer cell death 
[151]. Studies showing that transfection of one miRNA 
can contribute to increase the resistance to malaria in 
mice [140] suggest that miRNAs may be particularly 
interesting in seeking alternative therapeutic approaches 
given the dependence of apicomplexan over the host cel-
lular machinery to accomplish infection and complete 
their biological cycles. Since miRNAs also have a role in 
modulating immune responses against invading para-
sites, these could be potential targets to enhance host 
responses against P. falciparum or to make host cells 
refractory to parasite cyto-adhesion. In addition, this 
knowledge can provide important clues about the physi-
opathological mechanisms involved in other infections 
and help to dissect the biogenesis and function of miR-
NAs in normal human cells.
Conclusions
Although the enormous potential of miRNAs as a non-
invasive biomarker for several human diseases is well 
known, little has been done to decipher their relation-
ship with malaria pathogenesis. However, evidence is 
accumulating that host miRNA can be altered by parasite 
infections and be involved in the course and outcome of 
infectious diseases [142], pointing towards the potential 
of such small molecules as biomarkers for risk assess-
ment, diagnosis, prognosis, and monitoring of treatments 
for malaria infections. The application of miRNAs in bio-
fluids as a measure of tissue injury associated with para-
site sequestration may overcome the main rate-limiting 
roadblock due to the impossibility of measuring the pres-
ence and distribution of parasites in host organs unless 
post-mortem samples can be obtained. This approach 
opens the exciting possibility of identifying new diag-
nostic targets for patients at risk of severe malaria, and 
to distinguish severe malaria cases from those associated 
with other common pathologies, and also to facilitate 
treatment decisions. Overall, this knowledge will open up 
new horizons and opportunities for research, not only on 
malaria and other infectious diseases, but also on the role 
of human miRNAs. Future studies will likely contribute 
to identify key blocking events that may be targeted to 
develop new effective methods for inhibiting or revers-
ing the process of cyto-adhesion, as well as to develop 
miRNA-based biomarkers of diagnostic value for severe 
disease associated with P. falciparum sequestration.
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